Journal article
Novel targeted therapies for eosinophilic disorders
Abstract
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and …
Authors
Wechsler ME; Fulkerson PC; Bochner BS; Gauvreau GM; Gleich GJ; Henkel T; Kolbeck R; Mathur SK; Ortega H; Patel J
Journal
Journal of Allergy and Clinical Immunology, Vol. 130, No. 3, pp. 563–571
Publisher
Elsevier
Publication Date
September 2012
DOI
10.1016/j.jaci.2012.07.027
ISSN
0091-6749